Lars Lannfelt, Senior Professor of Geriatrics at Uppsala University, receives the Swedish Alzheimer’s Foundation’s Grand Research Prize 2019 of SEK 2.5 million. He receives the award for the drug candidate BAN2401, which has shown positive results in a Phase 2b study with 856 patients with early Alzheimer’s disease. The antibody is eliminating the soluble toxic aggregates of amyloid-beta, protofibrils, which are considered to be the cause of Alzheimer’s disease. Lars Lannfelt founded BioArctic in 2003, together with Associate Professor Pär Gellerfors, and is still active in the company.
The Swedish Alzheimer’s Foundation’s motivation for the 2019 Grand Research Prize reads:
“This year’s recipient of the Swedish Alzheimer’s Foundation’s Grand Research Prize is Professor Lars Lannfelt. Professor Lannfelt is honored with the prize for his many years of research concerning the basic pathogenic changes in the brain in Alzheimer’s disease, how they can be caused by genetic changes and how these changes can be diagnosed and targeted by new drugs. The whole world now hopes that one of these drugs will prove to be effective against Alzheimer’s disease, which we will soon know,” says Liselotte Jansson, General Secretary of the Swedish Alzheimer’s Foundation.
“I am extremely happy and honored to receive this very nice prize for my research,” says Lars Lannfelt, Senior Vice President University Collaborations at BioArctic.
Please read more here (in Swedish).